HK1160116A1 - Pyrrolo[2,3-d]pyrimidine compounds [23-d] - Google Patents

Pyrrolo[2,3-d]pyrimidine compounds [23-d]

Info

Publication number
HK1160116A1
HK1160116A1 HK12100393.9A HK12100393A HK1160116A1 HK 1160116 A1 HK1160116 A1 HK 1160116A1 HK 12100393 A HK12100393 A HK 12100393A HK 1160116 A1 HK1160116 A1 HK 1160116A1
Authority
HK
Hong Kong
Prior art keywords
pyrrolo
pyrimidine compounds
pyrimidine
compounds
Prior art date
Application number
HK12100393.9A
Other languages
English (en)
Chinese (zh)
Inventor
帕梅拉．喬．柏林斯基
馬修．約瑟夫．比爾施梅爾
杰里．韋恩．鮑曼
安德里亞．喬伊．岡扎勒茲
史蒂文．格倫．凱夢玲
唐納德．韋恩．曼恩
馬克．約瑟夫．米特恩-弗里
Original Assignee
碩騰有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41259411&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1160116(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 碩騰有限責任公司 filed Critical 碩騰有限責任公司
Publication of HK1160116A1 publication Critical patent/HK1160116A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK12100393.9A 2008-08-20 2012-01-13 Pyrrolo[2,3-d]pyrimidine compounds [23-d] HK1160116A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9037108P 2008-08-20 2008-08-20
PCT/IB2009/053514 WO2010020905A1 (fr) 2008-08-20 2009-08-10 Composés pyrrolo[2,3-d]pyrimidines

Publications (1)

Publication Number Publication Date
HK1160116A1 true HK1160116A1 (en) 2012-08-10

Family

ID=41259411

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12100393.9A HK1160116A1 (en) 2008-08-20 2012-01-13 Pyrrolo[2,3-d]pyrimidine compounds [23-d]

Country Status (27)

Country Link
US (4) US8133899B2 (fr)
EP (1) EP2384326B1 (fr)
JP (1) JP4884570B2 (fr)
KR (1) KR101335843B1 (fr)
CN (1) CN102131812B (fr)
AR (2) AR073073A1 (fr)
AU (1) AU2009283844B2 (fr)
BR (1) BRPI0917459B1 (fr)
CA (1) CA2733359C (fr)
CL (1) CL2011000353A1 (fr)
CO (1) CO6331437A2 (fr)
DK (1) DK2384326T3 (fr)
EC (1) ECSP11010904A (fr)
ES (1) ES2467109T3 (fr)
HK (1) HK1160116A1 (fr)
HR (1) HRP20140395T1 (fr)
ME (1) ME01269B (fr)
MX (1) MX2011001904A (fr)
NZ (1) NZ605292A (fr)
PL (1) PL2384326T3 (fr)
PT (1) PT2384326E (fr)
RS (1) RS53382B (fr)
RU (1) RU2493157C2 (fr)
SI (1) SI2384326T1 (fr)
UY (1) UY32059A (fr)
WO (1) WO2010020905A1 (fr)
ZA (1) ZA201101701B (fr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2474545T (lt) 2005-12-13 2017-02-27 Incyte Holdings Corporation Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
CA2689663C (fr) 2007-06-13 2016-08-09 Incyte Corporation Sels de l'inhibiteur (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile de la janus kinase
MX349923B (es) 2009-04-03 2017-08-21 Hoffmann La Roche Composiciones del ácido propano-1-sulfónico {3-[5-(4-cloro-fenil)- 1h-pirrolo [2,3-b]-piridina-3-carbonil]-2,4-difluoro-fenil]-amida y el uso de las mismas.
DK2432472T3 (da) 2009-05-22 2019-11-18 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer
BRPI1012159B1 (pt) 2009-05-22 2022-01-25 Incyte Holdings Corporation Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011045702A1 (fr) * 2009-10-15 2011-04-21 Pfizer Inc. Composés pyrrolo[2,3-d]pyrimidine
ES2633317T3 (es) 2009-11-06 2017-09-20 Plexxikon, Inc. Compuestos y métodos para la modulación de quinasas, e indicaciones para ello
CA2782720A1 (fr) * 2009-12-18 2011-06-23 Pfizer Inc. Composes pyrrolo[2,3-d]pyrimidines
AU2011219452B2 (en) * 2010-02-24 2014-05-29 Zoetis Llc Veterinary compositions
KR20220015492A (ko) 2010-03-10 2022-02-08 인사이트 홀딩스 코포레이션 Ｊａｋ１ 저해제로서의 피페리딘­４­일 아제티딘 유도체
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
PL2574168T3 (pl) 2010-05-21 2016-10-31 Preparaty inhibitora kinazy janusowej do stosowania miejscowego
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
CA2818542A1 (fr) 2010-11-19 2012-05-24 Incyte Corporation Derives pyrrolopyridine et pyrrolopyrimidine a substitution cyclobutyle utilises comme inhibiteurs des jak
PT2672967T (pt) 2011-02-07 2018-12-07 Plexxikon Inc Compostos e métodos de modulação da quinase e suas indicações
US8637038B2 (en) 2011-04-12 2014-01-28 Rigel Pharmaceuticals, Inc. Methods for inhibiting allograft rejection
EP2721028B1 (fr) 2011-06-20 2015-11-04 Incyte Corporation Dérivés d'azétidinyl-phényl-, de pyridyl- ou de pyrazinyl-carboxamide en tant qu'inhibiteurs des jak
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2013173720A1 (fr) 2012-05-18 2013-11-21 Incyte Corporation Dérivés de pyrrolopyridine et de pyrrolopyrimidine substitués par un pipéridinylcyclobutyle à titre d'inhibiteurs jak
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
MX349943B (es) * 2012-07-17 2017-08-21 Glaxosmithkline Ip No 2 Ltd Indolcarbonitrilos como moduladores selectivos del receptor de androgeno.
EP2874630B1 (fr) * 2012-07-20 2018-12-05 Zoetis Services LLC Régime posologique destiné à des inhibiteurs de la janus kinase (jak)
PE20200175A1 (es) 2012-11-15 2020-01-24 Incyte Holdings Corp Formas de dosificacion de ruxolitinib de liberacion sostenida
CN103896946B (zh) * 2012-12-28 2018-04-03 浙江导明医药科技有限公司 用于预防及治疗多种自身免疫疾病的新化合物
WO2014118388A1 (fr) 2013-02-04 2014-08-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes d'analyse de l'activité jak2 dans des globules rouges sanguins et leurs utilisations
NZ710411A (en) 2013-02-22 2017-11-24 Pfizer Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
UA120162C2 (uk) 2013-03-06 2019-10-25 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки при отриманні інгібітора jak
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
CA3155500A1 (fr) 2013-08-07 2015-02-12 Incyte Corporation Formes galeniques a liberation prolongee pour un inhibiteur jak1
EP2924026A1 (fr) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylméthylcyclohexanes comme inhibiteurs de JAK
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
EP3180344B1 (fr) 2014-08-12 2019-09-18 Pfizer Inc Dérivés de pyrrolo[2,3-d]pyrimidine utiles pour inhiber la janus kinase
EP3248980B1 (fr) * 2015-01-20 2023-09-06 Wuxi Fortune Pharmaceutical Co., Ltd Inhibiteur de jak
EP3290418B1 (fr) 2015-04-29 2019-05-15 Wuxi Fortune Pharmaceutical Co., Ltd Inhibiteurs de janus kinase (jak)
KR102081272B1 (ko) 2015-05-29 2020-02-25 우시 포춘 파마슈티컬 컴퍼니 리미티드 Janus 키나아제 억제제
WO2017013270A1 (fr) 2015-07-23 2017-01-26 Universite De Strasbourg Utilisation d'un inhibiteur de la signalisation de la leptine pour la protection des reins de patients atteints de ciliopathie
CN108602758B (zh) * 2016-02-05 2021-01-26 斯福瑞股份公司 制备反式-4-氨基-1-环己烷基羧酸及其衍生物的方法
AU2017221193B2 (en) * 2016-02-16 2019-03-14 Zoetis Services Llc Process for preparing 7H-pyrrolo (2, 3-d) pyrimidine compounds
CN107365312B (zh) * 2016-05-13 2021-10-01 瑞博(杭州)医药科技有限公司 一种制备Oclacitinib的新方法
US10875847B2 (en) 2016-12-14 2020-12-29 Intervet Inc. Aminopyrazoles as selective janus kinase inhibitors
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
WO2018167283A1 (fr) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés pour le diagnostic et le traitement d'un remodelage neuronal associé à un adénocarcinome canalaire pancréatique
WO2018189335A1 (fr) 2017-04-13 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de diagnostic et de traitement d'un adénocarcinome canalaire pancréatique
CN110662747A (zh) 2017-05-23 2020-01-07 施万生物制药研发Ip有限责任公司 Janus激酶抑制剂的葡糖苷酸前药
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CN112105608B (zh) 2018-01-30 2023-07-14 因赛特公司 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法
MA52011A (fr) 2018-03-16 2021-01-20 Zoetis Services Llc Vaccins peptidiques contre l'interleukine-31
CA3093539A1 (fr) 2018-03-16 2019-09-19 Zoetis Services Llc Anticorps monoclonaux anti-interleukine-31 a usage veterinaire
MX2020010322A (es) 2018-03-30 2022-11-30 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
WO2020092015A1 (fr) 2018-11-02 2020-05-07 University Of Rochester Atténuation thérapeutique d'une infection épithéliale
CN113272306A (zh) * 2018-11-05 2021-08-17 爱维斯塔制药解决方案有限公司 化学化合物
NL2022471B1 (en) 2019-01-29 2020-08-18 Vationpharma B V Solid state forms of oclacitinib
CN111499641B (zh) * 2019-01-30 2021-06-04 格格巫（珠海）生物科技有限公司 一种jak抑制剂及其制备方法
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
EP4077380A1 (fr) 2019-12-20 2022-10-26 Intervet International B.V. Anticorps bispécifiques caninisés et partenaires de liaison bispécifiques pour le traitement de la dermatite atopique
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN112279854B (zh) * 2020-08-25 2022-04-05 常州齐晖药业有限公司 一种7H-吡咯并[2,3-d]嘧啶化合物的制备方法
JP2023545182A (ja) 2020-10-15 2023-10-26 インターベット インターナショナル ベー． フェー． イヌインターロイキン－３１受容体アルファに対するイヌ化ラット抗体
JP2023554665A (ja) 2020-12-18 2023-12-28 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド ホウ素含有ピラゾール化合物、それらを含む組成物、それらの方法及び使用
EP4294462A1 (fr) 2021-02-22 2023-12-27 Zoetis Services LLC Modèle de prurit induit par l'il-31 équine
AU2022331810A1 (en) 2021-08-20 2024-02-29 Intervet International B.V. Fusion proteins for treating atopic dermatitis
CA3239826A1 (fr) 2021-12-16 2023-06-22 Mohamad Morsey Anticorps caninises contre le recepteur alpha ii de l'interleukine-31 canine
AU2022418280A1 (en) 2021-12-24 2024-06-13 Intervet International B.V. Use of aminopyrazole compounds
CN114605420B (zh) * 2022-04-25 2024-07-12 江苏慧聚药业股份有限公司 马来酸奥拉替尼的合成方法
CN118255769A (zh) * 2022-12-28 2024-06-28 格格巫（珠海）生物科技有限公司 一种立体异构体的制备方法及中间体

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) * 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
GB915303A (en) 1958-03-13 1963-01-09 Wellcome Found Pyrrolo[2,3-d]pyrimidine derivatives and the manufacture thereof
US3670079A (en) * 1970-10-06 1972-06-13 Merck & Co Inc Anabolic agents
US4997936A (en) * 1977-10-19 1991-03-05 Merck & Co., Inc. 2-carbamimidoyl-6-substituted-1-carbadethiapen-2-em-3-carboxylic acids
US4456464A (en) * 1982-05-19 1984-06-26 Zoecon Corporation Phenoxy- and pyridyloxy-phenoxyalkyl phosphinates and related sulfur compounds for weed control
US4526608A (en) * 1982-07-14 1985-07-02 Zoecon Corporation Certain 2-pyridyloxyphenyl-oximino-ether-carboxylates, herbicidal compositions containing same and their herbicidal method of use
US4590282A (en) * 1984-09-24 1986-05-20 Sandoz Ltd. Pest control agents
US4933339A (en) * 1985-08-21 1990-06-12 Rohm And Haas Company (2-cyano-2-arylethyl)pyridine compounds useful in controlling fungicidal activity
CA1328333C (fr) * 1988-03-04 1994-04-05 Quirico Branca Derives d'acide amine
NO169490C (no) 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
US4879309A (en) * 1988-09-27 1989-11-07 Schering Corporation Mercapto-acylamino acids as antihypertensives
JP2983254B2 (ja) * 1989-06-14 1999-11-29 武田薬品工業株式会社 ピロロ〔２，３―ｄ〕ピリミジン誘導体の製造法およびその中間体
US5356903A (en) * 1993-04-22 1994-10-18 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolines
US6136595A (en) * 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5389509A (en) * 1993-10-04 1995-02-14 Eastman Kodak Company Ultrathin high chloride tabular grain emulsions
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
EP0682027B1 (fr) 1994-05-03 1997-10-15 Novartis AG Dérivés de la pyrrolopyrimidine avec une activité anti-proliférative
JP3290666B2 (ja) 1995-06-07 2002-06-10 ファイザー・インコーポレーテッド 複素環式の縮合環ピリミジン誘導体
KR19990028709A (ko) 1995-07-05 1999-04-15 미리암 디. 메코너헤이 살진균 피리미디논
CZ1598A3 (cs) 1995-07-06 1998-04-15 Novartis Ag Pyrrolopyrimidiny a způsoby jejich přípravy
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
CN1168138A (zh) 1995-11-14 1997-12-17 法玛西雅厄普约翰公司 芳基和杂芳基嘌呤化合物
EP0888349B1 (fr) 1996-01-23 2002-05-22 Novartis AG Pyrrolopyrimidines et leurs procedes de preparation
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
AU1794697A (en) 1996-03-06 1997-09-22 Novartis Ag 7-alkyl-pyrrolo{2,3-d}pyrimidines
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EA199900021A1 (ru) 1996-07-13 1999-08-26 Глаксо, Груп Лимитед Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
DK0938486T3 (da) * 1996-08-23 2008-07-07 Novartis Ag Substituerede pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
EP0946554A1 (fr) 1996-11-27 1999-10-06 Pfizer Inc. Derives de pyrimidines bicycliques fusionnes
WO1998033798A2 (fr) 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3d]pyrimidines et 4-aminopyrimidines en tant qu'inhibiteurs de la proliferation cellulaire
AU6568398A (en) * 1997-03-24 1998-10-20 Pharmacia & Upjohn Company Method for identifying inhibitors of jak2/cytokine receptor binding
EP1068206A1 (fr) 1998-04-02 2001-01-17 Neurogen Corporation Derives aminoalkyle substitues de pyrrolo 2,3-b]pyridine et pyrrolo 2,3-d]pyrimidine: modulateurs de recepteurs de crf1
AU4317399A (en) 1998-05-28 1999-12-13 Parker Hughes Institute Quinazolines for treating brain tumor
AU3951899A (en) * 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
AU4851599A (en) 1998-06-30 2000-01-17 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
MXPA01001893A (es) 1998-08-21 2002-04-24 Parker Hughes Inst Derivados de quinazolina.
JP2002526500A (ja) 1998-09-18 2002-08-20 ビーエーエスエフ アクチェンゲゼルシャフト プロテインキナーゼ阻害剤としてのピロロピリミジン
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
CA2379640C (fr) * 1999-09-30 2006-11-28 Neurogen Corporation Heterocycles a substitution alkylene-diamine
AP1905A (en) * 1999-12-10 2008-10-20 Pfizer Prod Inc Pyrrolo[2,3-d] Pyrimidine Compounds.
UA74370C2 (uk) * 2000-06-26 2005-12-15 Пфайзер Продактс Інк. Піроло(2,3-d)піримідинові сполуки як імуносупресори
HU230302B1 (hu) * 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
US7301023B2 (en) * 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GB0119249D0 (en) * 2001-08-07 2001-10-03 Novartis Ag Organic compounds
GT200200234A (es) * 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
BR0316487A (pt) * 2002-11-26 2005-10-11 Pfizer Prod Inc Método todo de tratamento da rejeição de transplantes
US7253166B2 (en) * 2003-04-22 2007-08-07 Irm Llc 6-phenyl-7H-pyrrolo[2,3-d]pyrimidine compounds that induce neuronal differentiation in embryonic stem cells
WO2005020921A2 (fr) * 2003-08-29 2005-03-10 Exelixis, Inc. Modulateurs c-kit et leurs procedes d'utilisation
EP1734967A2 (fr) * 2003-12-17 2006-12-27 Pfizer Products Incorporated Methode pour traiter le rejet de greffe(en) pyrrolo [2,3-d] pyrimidine compounds for treating transplant rejection
EP1715871A1 (fr) * 2003-12-22 2006-11-02 Gilead Sciences, Inc. Conjugues de phosphonate inhibiteurs de kinase
CA2553724A1 (fr) * 2004-02-03 2005-08-18 Abbott Laboratories Utilisation d'aminobenzoxazoles comme agents therapeutiques
CA2572331A1 (fr) * 2004-07-02 2006-02-09 Exelixis, Inc. Modulateurs de c-met et leur methode d'utilisation
JP2008508358A (ja) * 2004-08-02 2008-03-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アリール−アミノ置換ピロロピリミジンマルチキナーゼ阻害化合物
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
WO2008089307A2 (fr) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Méthodes et compositions utilisés dans le traitement de la douleur, de l'inflammation et du cancer
WO2008089310A2 (fr) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Méthodes et compositions utilisées dans le traitement de troubles corporels

Also Published As

Publication number Publication date
UY32059A (es) 2010-03-26
AR073073A1 (es) 2010-10-13
US8133899B2 (en) 2012-03-13
US20100075996A1 (en) 2010-03-25
DK2384326T3 (da) 2014-05-05
CA2733359C (fr) 2014-08-05
US20150374701A1 (en) 2015-12-31
AU2009283844A1 (en) 2010-02-25
EP2384326A1 (fr) 2011-11-09
CO6331437A2 (es) 2011-10-20
MX2011001904A (es) 2011-03-29
US9161939B2 (en) 2015-10-20
HRP20140395T1 (hr) 2014-06-06
PT2384326E (pt) 2014-06-09
AU2009283844B2 (en) 2013-09-05
CN102131812B (zh) 2014-04-09
US20150148357A1 (en) 2015-05-28
RU2011106331A (ru) 2012-08-27
PL2384326T3 (pl) 2014-09-30
WO2010020905A1 (fr) 2010-02-25
RS53382B (en) 2014-10-31
ZA201101701B (en) 2012-05-30
CA2733359A1 (fr) 2010-02-25
JP2012500253A (ja) 2012-01-05
US9271981B2 (en) 2016-03-01
US20120122901A1 (en) 2012-05-17
CL2011000353A1 (es) 2011-05-06
ES2467109T3 (es) 2014-06-11
BRPI0917459B1 (pt) 2017-09-12
AR106252A2 (es) 2017-12-27
KR101335843B1 (ko) 2013-12-02
NZ605292A (en) 2014-06-27
KR20110043697A (ko) 2011-04-27
ME01269B (me) 2013-06-20
ECSP11010904A (es) 2011-04-29
BRPI0917459A2 (pt) 2015-12-01
EP2384326B1 (fr) 2014-04-23
SI2384326T1 (sl) 2014-06-30
RU2493157C2 (ru) 2013-09-20
CN102131812A (zh) 2011-07-20
JP4884570B2 (ja) 2012-02-29
US8987283B2 (en) 2015-03-24

Similar Documents

Publication Publication Date Title
HK1160116A1 (en) Pyrrolo[2,3-d]pyrimidine compounds [23-d]
ZA201202718B (en) Pyrrolo[2,3-d]pyrimidine compounds
IL257410A (en) Pyrazolo [1, 5 – a ] pyrimidines as antiviral agents
IL278119B (en) Disubstituted pyrazolo[5.1–a]pyrimidine compounds as trk kinase inhibitors
HK1143154A1 (en) Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors b[23-d]
ZA201004368B (en) Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors
ZA201104853B (en) 2,5-diamino-substituted pyrido[4,3-d]pyrimidines as autotaxin inhibitors against cancer
ZA201200982B (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
EP2608669A4 (fr) Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor
ZA201004823B (en) Novel pyrazolo [3,4-d]pyrimidine derivatives as anti-cancer agents
EP2525659A4 (fr) Composés pyrazolo[1,5-a]pyrimidines en tant qu'inhibiteurs de mtor
BRPI0822239A2 (pt) Composto de pirazolo[1,5-a] pirimidina
ZA201101550B (en) 4-amino-3-(imidazolyl)-pyrazolo[3,4-d]pyrimidines
SI2167470T1 (sl) Triazolo(1,5-a)kinolini kot adenozin A3 receptorski ligandi
EP2523552A4 (fr) Pyrazolo[1,5-a]pyrimidines comme inhibiteurs de mark
EP2511276A4 (fr) Dérivé de pyrrolo[2,3-d]pyrimidine
IL206666A0 (en) N-PHENYLIMIDAZO[1,2-a]PYRIDINE-2-
IL206668A0 (en) N-PHENYLIMIDAZO[1,2-a]PYRIDINE-2-